ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, in Baltimore, MD.
“These data underscore our commitment to developing scalable solutions and capabilities to accelerate cell and gene therapy development,” said Mitchell Finer, Ph.D., President, R&D, ElevateBio. “As a technology-forward company, we’re thrilled to showcase these latest advancements that are fueling the programs of our partners and moving the industry forward.”
Presentation Details:
Title: Early Characterization of Research-Grade AAV6 Productions Allows for Manufacturing Alignment During Candidate Nomination
Poster/Abstract #: 1435
Session: AAV Vectors - Virology and Vectorology
Date/time: Friday, May 10, 2024 at 12:00-7:00 p.m. ET
Title: Development and Scale Up of a Robust End-to-End Manufacturing Process for High Quality AAV Production
Poster/Abstract #: 1534
Session: AAV Vectors - Product Development Manufacturing and Approval Considerations
Date/time: Friday, May 10, 2024 at 12:00-7:00 p.m. ET
Title: Design and Production of Circular RNAs (circRNAs) with Validated Functional Activity in Cell Models
Poster/Abstract #: 1711
Session: Oligonucleotide Therapeutics
Date/time: Friday, May 10, 2024 at 12:00-7:00 p.m. ET
Title: A Rapid and Scalable 96-Well Platform to Screen CARs and TCRs
Poster/Abstract #: 1894
Session: Molecular and Cellular Methods
Date/time: Friday, May 10, 2024 at 12:00-7:00 p.m. ET
About ElevateBio:
ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene editing platform; comprehensive cell engineering technologies; and an expanded viral and non-viral therapeutic delivery platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics.
ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit www.elevate.bio or follow ElevateBio on LinkedIn or Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422322176/en/
Source: ElevateBio
View this news release online at:
http://www.businesswire.com/news/home/20240422322176/en
